Stephen V Liu, MD· @StephenVLiu · X·· 1 天前评分70
正文 · 原文
Simultaneous publication @NEJM of #ESMO26 presentation from Dr. Shun Lu. Osimertinib + savolitinib superior to chemo in EGFR+ NSCLC post osimertinib with MET overexpression and/or amp: 338 randomized / 1746 screened: PFS 7.6 vs 5.4m, HR 0.55, OS HR 0.68
https://www.nejm.org/doi/full/10.1056/NEJMoa2611335
220 浏览 · 8 赞 · 3 转发 · 0 回复
来源：Stephen V Liu, MD · x.com